Richard J Gralla
Overview
Explore the profile of Richard J Gralla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
2587
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kennedy S, Goodall S, Lee S, DeAngelis C, Jocko A, Charbonneau F, et al.
Support Care Cancer
. 2024 Apr;
32(5):280.
PMID: 38594320
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of...
2.
Jordan K, Chan A, Gralla R, Jahn F, Rapoport B, Ruhlmann C, et al.
Support Care Cancer
. 2023 Dec;
32(1):53.
PMID: 38129530
Purpose: Our goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC/ESMO antiemetic update...
3.
Hollen P, Gralla R, Gentzler R, Hall R, Coyne B, Cheng H, et al.
Oncologist
. 2020 Oct;
26(3):224-230.
PMID: 33098189
Background: Thousands of patients annually receive treatment for advanced non-small cell lung cancer (NSCLC), but little is known about their views on the decision to receive that treatment, or regret....
4.
Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, et al.
Oncologist
. 2020 Mar;
25(3):e589-e597.
PMID: 32162813
Background: NEPA, a combination antiemetic of a neurokinin-1 (NK ) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5-HT RA, palonosetron] offers 5-day CINV prevention with a single dose. Fosnetupitant...
5.
Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis C, et al.
Future Oncol
. 2019 Jul;
15(20):2371-2383.
PMID: 31354046
We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT...
6.
7.
Reck M, Brahmer J, Bennett B, Taylor F, Penrod J, DeRosa M, et al.
Eur J Cancer
. 2018 Aug;
102:23-30.
PMID: 30103096
Background: Nivolumab, a programmed death-1 inhibitor, prolonged overall survival and had a favourable safety profile versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) in...
8.
Gralla R, Raftopoulos H
J Oncol Pract
. 2018 Feb;
5(3):130-133.
PMID: 29452040
New agents and studies have demonstrated benefit in improving antiemetic therapy. Incorporating evidence-based guideline recommendations and appropriate emesis assessments are key components to achieving the best practice.
9.
Recio-Boiles A, Galeas J, Goldwasser B, Sanchez K, Man L, Gentzler R, et al.
Support Care Cancer
. 2018 Feb;
26(7):2353-2359.
PMID: 29417293
Purpose: Ongoing cancer cachexia trials evaluate sarcopenia by skeletal muscle index (SMI) at the L3 vertebrae level, commonly used as a standard. Routine chest CT institutional protocols widely differ in...
10.
Gelhorn H, Skalicky A, Balantac Z, Eremenco S, Cimms T, Halling K, et al.
Support Care Cancer
. 2018 Feb;
26(7):2229-2238.
PMID: 29392480
Purpose: Obtaining qualitative data directly from the patient perspective enhances the content validity of patient-reported outcome (PRO) instruments. The objective of this qualitative study was to evaluate the content validity...